Check-Cap Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Check-Cap in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Check-Cap stock.
View analyst ratings for Check-Cap or view top-rated stocks.

Wall Street analysts have given Check-Cap a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Check-Cap wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Check-Cap is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Check-Cap.

Check-Cap Ltd. (NASDAQ:CHEK) posted its earnings results on Wednesday, May, 12th. The medical research company reported ($0.05) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.05).
View Check-Cap's earnings history.

Check-Cap's stock was trading at $1.32 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CHEK shares have increased by 22.7% and is now trading at $1.62.
View which stocks have been most impacted by COVID-19.

Check-Cap shares reverse split on Wednesday, April 4th 2018. The 1-12 reverse split was announced on Wednesday, April 4th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 3rd 2018. An investor that had 100 shares of Check-Cap stock prior to the reverse split would have 8 shares after the split.

2 Wall Street analysts have issued twelve-month price targets for Check-Cap's shares. Their forecasts range from $2.00 to $4.00. On average, they anticipate Check-Cap's stock price to reach $3.00 in the next year. This suggests a possible upside of 85.2% from the stock's current price.
View analysts' price targets for Check-Cap or view top-rated stocks among Wall Street analysts.

Some companies that are related to Check-Cap include Mustang Bio (MBIO), Arbutus Biopharma (ABUS), Aptose Biosciences (APTO), Theratechnologies (THERF), Fulcrum Therapeutics (FULC), Viemed Healthcare (VMD), Sernova (SEOVF), CorMedix (CRMD), Viemed Healthcare (VMD), Ovid Therapeutics (OVID), Sigilon Therapeutics (SGTX), Infinity Pharmaceuticals (INFI), Cardiff Oncology (CRDF), Cybin (CLXPF) and NantHealth (NH).
View all of CHEK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Check-Cap investors own include Alibaba Group (BABA), Navios Maritime Partners (NMM), New Residential Investment (NRZ), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Acasti Pharma (ACST), Avinger (AVGR), Biocept (BIOC) and Purple Biotech (KTOV).

(CHEK) raised $13 million in an initial public offering on Thursday, February 19th 2015. The company issued 1,200,000 shares at $10.00-$12.00 per share. Chardan Capital Markets and Maxim Group acted as the underwriters for the IPO and Feltl and Company was co-manager.

Check-Cap trades on the NASDAQ under the ticker symbol "CHEK."

Check-Cap's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.69%), Citadel Advisors LLC (0.30%), HighPoint Advisor Group LLC (0.14%), Goldman Sachs Group Inc. (0.13%), Perritt Capital Management Inc. (0.13%) and Squarepoint Ops LLC (0.10%).

CHEK stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, HighPoint Advisor Group LLC, and Perritt Capital Management Inc..

CHEK stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Citadel Advisors LLC, and Goldman Sachs Group Inc..

Shares of CHEK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHEK stock can currently be purchased for approximately $1.62.

Check-Cap has a market capitalization of $74.91 million. The medical research company earns $-13,850,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis.

Check-Cap employs 65 workers across the globe.

The official website for Check-Cap is www.check-cap.com.

Check-Cap is headquartered at 29 ABBA HUSHI AVE. P.O.BOX 1271, ISFIYA L3, 3009000.

Check-Cap's mailing address is 29 ABBA HUSHI AVE. P.O.BOX 1271, ISFIYA L3, 3009000. The medical research company can be reached via phone at 972546706451 or via email at [email protected]